Bromfield Sneider Wealth Advisors Purchases New Stake in Pfizer Inc. (NYSE:PFE)

Bromfield Sneider Wealth Advisors purchased a new stake in Pfizer Inc. (NYSE:PFEGet Rating) in the first quarter, HoldingsChannel.com reports. The fund purchased 1,947 shares of the biopharmaceutical company’s stock, valued at approximately $101,000.

A number of other hedge funds also recently bought and sold shares of PFE. Bank OZK grew its holdings in shares of Pfizer by 0.3% during the fourth quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock worth $4,067,000 after purchasing an additional 195 shares during the last quarter. TimeScale Financial Inc. boosted its holdings in Pfizer by 2.9% in the fourth quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock valued at $412,000 after acquiring an additional 196 shares during the last quarter. Bath Savings Trust Co boosted its holdings in Pfizer by 0.5% in the fourth quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company’s stock valued at $2,344,000 after acquiring an additional 200 shares during the last quarter. Fruth Investment Management boosted its holdings in Pfizer by 0.7% in the fourth quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $1,730,000 after acquiring an additional 200 shares during the last quarter. Finally, Winfield Associates Inc. boosted its holdings in Pfizer by 0.9% in the fourth quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock valued at $1,273,000 after acquiring an additional 200 shares during the last quarter. 66.50% of the stock is owned by institutional investors and hedge funds.

In other Pfizer news, SVP Jennifer B. Damico sold 4,000 shares of the firm’s stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $50.50, for a total value of $202,000.00. Following the completion of the transaction, the senior vice president now owns 15,064 shares in the company, valued at approximately $760,732. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Jennifer B. Damico sold 4,218 shares of the firm’s stock in a transaction dated Tuesday, June 7th. The stock was sold at an average price of $53.96, for a total value of $227,603.28. Following the completion of the transaction, the senior vice president now owns 10,846 shares of the company’s stock, valued at approximately $585,250.16. The disclosure for this sale can be found here. Insiders have sold a total of 41,126 shares of company stock valued at $2,075,003 in the last quarter. 0.05% of the stock is owned by corporate insiders.

Shares of Pfizer stock opened at $49.07 on Thursday. Pfizer Inc. has a 1 year low of $38.82 and a 1 year high of $61.71. The firm has a market cap of $275.33 billion, a PE ratio of 11.25, a P/E/G ratio of 0.56 and a beta of 0.76. The stock has a fifty day moving average price of $50.57 and a 200-day moving average price of $52.22. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.39 and a quick ratio of 1.13.

Pfizer (NYSE:PFEGet Rating) last announced its earnings results on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.66 by ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The business had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. During the same period in the prior year, the business earned $0.93 earnings per share. The company’s revenue for the quarter was up 76.8% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 6.61 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, June 10th. Stockholders of record on Friday, May 13th were paid a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, May 12th. This represents a $1.60 annualized dividend and a dividend yield of 3.26%. Pfizer’s payout ratio is 36.70%.

PFE has been the topic of several analyst reports. JPMorgan Chase & Co. set a $57.00 target price on Pfizer in a report on Tuesday, May 3rd. The Goldman Sachs Group set a $51.00 price target on Pfizer in a report on Wednesday, May 25th. Morgan Stanley assumed coverage on Pfizer in a report on Wednesday, April 6th. They set an “equal weight” rating and a $55.00 price target on the stock. Barclays set a $52.00 target price on Pfizer in a research report on Tuesday, May 17th. Finally, SVB Leerink assumed coverage on Pfizer in a research report on Monday, May 23rd. They set a “market perform” rating and a $55.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $57.26.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Read More

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.